[{"id":"264c1f17-e960-45e7-a8ad-1364b1706dfb","acronym":"NKX101-101","url":"https://clinicaltrials.gov/study/NCT04623944","created_at":"2022-04-15T16:52:42.805Z","updated_at":"2024-07-02T16:35:10.692Z","phase":"Phase 1","brief_title":"NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS","source_id_and_acronym":"NCT04623944 - NKX101-101","lead_sponsor":"Nkarta Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • decitabine • fludarabine IV • NKX101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 09/21/2020","start_date":" 09/21/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2039","study_completion_date":" 07/01/2039","last_update_posted":"2024-04-09"}]